Portal de Periódicos da CAPES

Long-term effectiveness of photodynamic therapy by using a hydrophilic photosensitizer ATX-S10(Na) against experimental choroidal neovascularization in rats

2000; Wiley; Volume: 26; Issue: 1 Linguagem: Inglês

10.1002/(sici)1096-9101(2000)26

1096-9101

Masakazu Kanai, Akira Obana, Yuko Gohto, Satoshi Nagata, Tokuhiko Miki, Kenji Kaneda, Susumu Nakajima,

Nanoplatforms for cancer theranostics

Background and Objective We previously demonstrated that a hydrophilic photosensitizer ATX-S10 had a potent photodynamic effect. This study was designed to reveal the long-term effectiveness of photodynamic therapy (PDT) with this agent in occluding choroidal neovascularization (CNV) and its selectivity in the neovascular tissue. Study Design/Materials and Methods Experimental CNV was induced by intense photocoagulation in rat eyes. Immediately or 2 hours after intravenous injection of 8 mg/kg body weight of ATX-S10(Na), a cis isomer of ATX-S10, eyes were irradiated by a diode laser at the radiance of 3.25–65.3 J/cm2 Vascular occlusion was identified by fundus photography, fluorescein angiography, and histology at 1, 3, 7, 14, and 28 days after PDT. As controls, non-neovascular eyes were subjected to PDT and similarly analyzed. Results By using the following treatment parameters, PDT with ATX-S10(Na) successfully occluded CNV without causing occlusion of retinal capillaries for 28 days; 7.4 and 19.6 J/cm2 immediately after dye injection and 36.7 and 65.3 J/cm2 2 hours after injection. Although these conditions also caused occlusion of normal choriocapillaries and mild injuries of retinal vessels, retinal pigment epithelium, and photoreceptors at 1 day, retinal vessels and pigment epithelial cells recovered from damages by 28 days. No injuries were found in the inner retina. Conclusion In optimal treatment conditions, PDT with ATX-S10(Na) can induce long-term, selective occlusion of CNV without causing irreversible damages in the inner retina. Lasers Surg. Med. 26:48–57, 2000. © 2000 Wiley-Liss, Inc.